Lake Street maintains Buy on Kopin stock, price target $2.50

Published 01/23/2025, 09:41 AM
KOPN
-

On Thursday, Lake Street Capital Markets sustained its Buy rating on Kopin Corp (NASDAQ:KOPN) with a steady price target of $2.50, falling within the current analyst range of $2.00-$3.00. The stock, which has surged 23.5% in the past week, shows significant momentum as analysts at the firm cited Kopin's recent show of interest in the U.S. Army's Integrated Visual Augmentation System (IVAS) Next (LON:NXT) Program as a positive indicator. Following a week of investor meetings with Kopin's Chairman and CEO Michael Murray, the firm expressed confidence in the company's prospects, particularly within the defense sector. InvestingPro analysis reveals 12 key investment factors for KOPN, including its volatile trading pattern and strong recent returns.

Lake Street analysts believe that Kopin's defense revenue, which saw a year-over-year increase of 109% in the third quarter and 77% year-to-date through the same period, will continue its upward trajectory. With a market capitalization of $285 million and a beta of 2.7, the company shows significant growth potential despite its current gross profit margin of 9.8%. They emphasized Kopin's unique position as the only U.S.-owned microdisplay company after Samsung (KS:005930)'s acquisition of eMagin (NYSE:EMAN) in 2023. This distinction, along with the company's longstanding relationship with the defense market and a broad customer base, is seen as a strategic advantage in securing government contracts.

The analysts also pointed to the potential for significant stock appreciation as the market begins to recognize Kopin's expanding order book, operational leverage improvements, and visibility into transformative opportunities. Despite the ongoing legal case that could result in a $24.8 million payout, Lake Street believes the stock is already factoring in this worst-case scenario. For deeper insights into Kopin's financial health and growth prospects, InvestingPro subscribers can access comprehensive research reports and real-time financial metrics that help evaluate the company's true potential.

Kopin's pipeline includes opportunities such as continued engagement with the F-35 program, additional orders for weapons sight programs, participation in the Lockheed missile program, the Abrams tank upgrade, and the IVAS Next initiative. The company's recent announcement on January 14th of a $2 million follow-on order for pilot helmet-mounted displays for rotary and fixed-wing aircraft reinforces the analyst's positive outlook on Kopin's order momentum. Based on InvestingPro's Fair Value analysis, the stock currently appears overvalued, though strong recent performance and upcoming catalysts could justify premium valuations.

In other recent news, Kopin Corporation has shown significant developments on several fronts. The company reported a 26% year-over-year increase in revenue to $13.3 million in the third quarter, primarily driven by a 109% surge in defense product revenues. Despite these gains, Kopin experienced a net loss of $3.5 million for the quarter, attributed to increased legal fees and other expenses.

Kopin has also caught the attention of the U.S. Army with its interest in the Integrated Visual Augmentation System (IVAS) Next Program. The company's defense revenue was up 109% YoY in the third quarter, positioning it favorably in the eyes of the U.S. government. Analyst Jaeson Schmidt from Lake Street Capital Markets maintained a Buy rating on Kopin, citing the company's growing traction in the defense sector.

The company also announced new compensatory arrangements for its top executives, including CEO Michael Murray, who received a significant award of restricted stock units and stock options. In addition, Kopin has appointed BDO USA, P.C. as its new independent registered public accounting firm for the fiscal year ending December 28, 2024.

Finally, analysts at Canaccord Genuity initiated coverage on Kopin with a Buy rating, highlighting the company's defense-related projects and expansion into the medical and consumer markets. These are the latest in a series of recent developments for Kopin Corporation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.